DAIICHI SANKYO COMPANY,LIMITED
FY2026 Q2 Financial Results Presentation
Filed with TSE ·
Watch Daiichi Sankyo's latest callDaiichi Sankyo (Tokyo:4568) Q1 2026 Earnings Call · Replay · Jul 31Read the transcript of Daiichi Sankyo (Tokyo:4568) Q1 2026 Earnings Call6ix is reading this filing.
View original source (TDnet)Daiichi Sankyo Company, Limited on 6ix
In the deck
Earlier from Daiichi Sankyo
- Consolidated Financial Results for the First Six Months of the Year Ending March 31,2027(Fiscal 2026)
- Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types
- Notice Regarding NTK’s Filing of Appeal in Damages Claim Against Daiichi Sankyo
- Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn
- Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer
Later from Daiichi Sankyo
All Daiichi Sankyo news releasesFollow Daiichi Sankyo into a list and get an email when it puts out news.
Follow Daiichi Sankyo